Anna Walz is a 25+ year veteran in the pharmaceutical industry. She is the Founder and CEO Emeritus of MedEvoke, a MEDISTRAVA Company (Medical Division of Huntsworth). MedEvoke is a global medical consulting firm dedicated to working with Medical Affairs leaders to drive alignment through development of clear medical strategies that can be globally communicated, measured, and analyzed. This has, for the first time, enabled Medial Affairs to track the impact of internal efforts on the external scientific and digital exchanges. Anna currently serves as Senior Strategic Advisor to MEDISTRAVA and provides professional guidance on the formation of a cross-company Medical Analytics Function that will overlay the community of medical affairs agencies within the healthcare division of Huntsworth. Her external responsibilities include working with key clients and professional organizations on market implementation and validation of the medical analytics function. Internal responsibilities include providing input on annual strategy planning process and relevant roll-out workstreams. Anna also serves of the Board of Directors for Healios AG, a Swiss-based medical device software manufacturer that is dedicated to finding solutions in clinical research and patient monitoring through innovative digital technologies. Anna, who often speaks on the topics of medical strategy, launch excellence, impact metrics for medical affairs, female entrepreneurship, and diversity in the biosciences, is also a regular guest-lecturer on the topic of Pharmacology & Drug Marketing at the Rutgers Medical School. In addition to speaking, Anna has a keen interest in her own continuing education and is a graduate of both the Tuck-WBENC Executive Education program and the Entrepreneurial Master’s Program (EMP), a joint collaboration of the Entrepreneurs’ Organization (EO) and the Massachusetts Institute of Technology (MIT). Anna has been one of the most vocal champions for MAPS since its inception, has served as Co-Chair of the Standards & Guidance Committee, and is currently serving on the organization’s Board of Directors and on the Fund Development Committee.